MORPHOLOGICAL CONFIRMATION OF MECHANISMS OF PROTECTIVE ACTION OF L-ORNITHINE L-ASPARTATE IN LIVER CIRRHOSIS
DOI:
https://doi.org/10.11603/1811-2471.2021.v.i2.12203Keywords:
liver cirrhosis, L-ornithine L-aspartate, L-NAME, DL-α-DifluoromethylornithineAbstract
Chronic hepatitis B or C, alcoholic hepatitis, diabetes, obesity, chronic diseases of the biliary tract, autoimmune diseases, etc. – diseases that can be complicated by liver cirrhosis. This pathology ranks first among the causes of death from diseases of the gastrointestinal tract.
The aim – to establish morphological changes in the liver in experimental cirrhosis with the administration of L-ornithine-L-aspartate (LOLA) in combination with modulators of nitric oxide or polyamine synthesis.
Material and Methods. Animals with simulated cirrhosis were divided into groups administered LOLA at a dose of 200 mg/kg for 10 days; who together with LOLA 200 mg/kg was administered L-NAME at a dose of 10 mg/kg for 10 days; which together with LOLA 200 mg/kg was administered and DFMO at a dose of 25 mg/kg. The histological structure of the liver was studied by staining with hematoxylin and eosin and Van Gizon-Weigert.
Results. Was found that the use of L-ornithine L-aspartate in experimental liver cirrhosis reduced the manifestations of dystrophic and necrotic changes in hepatocytes and reduced lymphohistiocytic infiltration of the fibrous stroma. The combined use of L-ornithine L-aspartate and a non-selective blocker of nitric oxide synthesis L-NAME in animals with CCL4 cirrhosis was accompanied by moderate structural changes in the form of predominantly dystrophic hepatocyte changes and a moderate decrease in fibrous fields in the liver parenchyma. The use of LOLA in combination with the inhibitor of DL-α-Difluoromethylornithine polyamine metabolism in animals with CCL4 cirrhosis was manifested by severe collagen stroma edema with significant lymphohistiocytic infiltration and pronounced dystrophic-necrotic changes in the liver.
Conclusions. Studies have shown that LOLA has a direct protective effect on the liver in experimental cirrhosis.
References
Denysyuk, V.I., Denysyuk, O.V., & Osyadla, E.S. (2012). Tsyroz pechinky: standarty diahnostyky ta likuvannia z urakhuvanniam rekomendatsii dokazovoi medytsyny [Cirrhosis of the liver: standards of diagnosis and treatment taking into account the recommendations of evidence-based medicine]. Hostri ta nevidkladni stany u praktytsi likaria – Acute and Urgent Conditions in the Practice of Medicine, 2-3 (31), 73-81 [in Ukrainian].
Butterworth, R.F. (2019). L-ornitynu-L-aspartat yak hepatoprotektor pry nealkoholnii zhyrovii khvorobi pechinky [L-ornithine-L-aspartate as a hepatoprotector in non-alcoholic fatty liver disease]. Zdorovia Ukrainy – Health of Ukraine, 3 (53), 30-31. Retrieved from: https://health-ua.com/article/43854-LorntinuLaspartat-yakgepato protektor-pri-nealkogolnj-zhirovj-hvorob-pechnki
Takigawa, M., Enomoto, M., Nishida, Y., Pan, H.O., Kinoshita, A., & Suzuki, F. (2014). Tumorangiogenesis and polyamines: α-Difluoromethylornithine, an irreversible inhibitor of ornitine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cell in vitro. Cancer Rec., 50 (13), 4131-4138.
Reznikov, O.H., Solovyov, A.I., Dobrelya, N.V., & Stefanov, O.V. (2006). Bioetychna ekspertyza doklinichnykh ta inshykh naukovykh doslidzhen, shcho vykonuiutsia na tvarynakh. Metodychni rekomendatsii [Bioethical examination of preclinical and other scientific research performed on animals. Methodical recommendations]. Visnyk farmakolohii ta farmatsii – Bulletin of Pharmacology and Pharmacy, 7, 47-61 [in Ukrainian].
Rybolovlev, Yu.R., & Rybolovlev, R.S. (1979). Dozirovaniye veshchestv dlya mlekopitayushchikh po konstantam biologicheskoy aktivnosti [Dosing of substances for mammals according to the constants of biological activity]. Doklady AN SSSR – Reports of the USSR Academy of Sciences, 247, 6, 1513-1516 [in Russian].
Najmi, A.K., Pillai, K.K., Pal, S.N., Akhtar, M., Aqil, M., & Sharma, M. (2010). Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats. Pharmacol. Indian J., 42 (6), 384-387. DOI: 10.4103/0253-7613.71926
Oleshchuk, O.M. (2014). Vplyv moduliatoriv syntezu oksydu azotu na biokhimichni pokaznyky funktsionalnoho stanu pechinky shchuriv [Influence of nitric oxide synthesis modulators on biochemical parameters of the functional state of the liver of rats]. Fiziol. zhurn. – Physiol. Magazine, 60, 2, 57-62 [in Ukrainian].
Yanish, Yu.V., Artamonova, A.B., & Zalyetok, S.P. (2016). Vplyv moduliatoriv metabolizmu arhininu i poliaminiv na aktyvnist arhinazy ta produktsiiu oksydiv azotu klitynamy astsytnoho raku Erlikha in vivo [Influence of modulators of arginine and polyamine metabolism on arginase activity and production of nitrogen oxides by Ehrlich ascites cancer cells in vivo]. Klynycheskaya onkolohyya – Clinical Oncology, 3, 89-91. Retrieved from: http:// nbuv.gov.ua/UJRN/klinonk-2016. 3-23
Bahrii, M.M., Dibrova, V.A., Popadynets, O.H., & Hryshchuk, M.I. (2016). Metodyky morfolohichnykh doslidzhen: monohrafiia [Methods of morphological research: monograph]. Vinnytsia: Nova knyha [in Ukrainian].
Datsko, V.А., Fedoniuk, L.Y., Ivankiv, Y.I., Kurylo, K.I., Volska, А.S., Malanchuk, S.L., & Oleshchuk, О.М. (2020). Experimental cirrhosis: liver morphology and function. Wiad. Lek., 73 (5), 947-952.
Tkach, S.M. (2013). L-ornitin-L-aspartat kak universalnyy gepatoprotektor-detoksikant s pleyotropnymi effektami [L-ornithine-L-aspartate as a universal hepatoprotector-detoxifier with pleiotropic effects]. Zdorovia Ukrainy – Health of Ukraine, 3. 60-61 [in Russian].
Chen, M.F., Li, R.C., Chen, C.H., & Gao, X.C. (2005). Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Di Yi Jun Yi Da Xue Xue Bao, 25 (6), 718-719.
Koruk, M., Aksoy, H., Akçay, F., & Onuk, M.D. (2002). Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis. Ann. Clin. Lab. Sci., 32 (3), 252-256.
Sarela, A.I., Mihaimeed, F.M., Batten, J.J., Davidson, B.R., & Mathie, R.T. (1999). Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut, 44 (9), 749-753.
Víteček, J., Lojek, A., Valacchi, G., & Kubala, L. (2012). Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediators Inflamm., 2012, 318087. DOI: https://doi.org/10.1155/2012/318087
Fuller, D.J., & Gerner E.W. (1982). Delayed sensitization to heat by inhibitors of polyamine-biosynthetic enzymes. Cancer Res., 42 (12), 5046-5049.
Kircheis, G., & Lüth, S. (2019). Pharmacokinetic and Pharmacodynamic Properties of l Ornithine l Aspartate (LOLA) in Hepatic Encephalopathy. Drugs, 79 (Suppl. 1), S23-S29. DOI: https://doi.org/10.1007/s40265-018-1023-2
Yevropeiska konventsiia pro zakhyst khrebetnykh tvaryn, shcho vykorystovuiutsia dlia doslidnytskykh abo inshykh naukovykh tsilei vid 18.03.1986 [European Convention for the Protection of Vertebrate Animals Used for Research or Other Scientific Purposes of 18 March 1986]. Verkhovna Rada Ukrainy, ofitsiinyi veb-portal: Mizhnarodni dokumenty (Rada Yevropy) – Verkhovna Rada of Ukraine, official web portal: International documents (Council of Europe). Retrieved from: http://zakon4.rada.gov.ua/laws/main?Find=1&sp=i&user=c393&text=%F2%E2%E0%F0%E8%ED&x=10&y=5 [in Ukrainian].
Verma, A.K. (1990). Inhibition of tumor promotion by dl-α-difluoromethylornithine, specific irreversible inhibitor of ornithine decarboxylase. Basic Life Sci., 52, 195-204. DOI: 10.1007/978-1-4615-9561-8_16
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
